INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.

Tyra Biosciences shares fell $4.72, or 17.66%, to $22.01 on September 9, 2026, after the company reported Grade 3 treatment-emergent adverse events in 14% of patients in the 60 mg once-daily cohort and 9% in the 50 mg cohort of its Phase 2 SURF302 study. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Tyra and certain officers or directors; the investigation is not a finding of wrongdoing.

Analysis

The investable issue is whether the safety signal compromises dose selection or the benefit-risk profile—not the law firm’s solicitation. The investigation is not a finding of misconduct, and by itself is unlikely to change cash flows; it may add headline volatility and increase scrutiny of how trial results were framed. The reported share-price reaction suggests meaningful disappointment was already priced on September 9, but the current price and subsequent disclosures are needed before judging whether that move is complete.

Over the next days to weeks, litigation headlines could pressure sentiment without resolving the clinical question. Over the next 1–3 months, the key evidence is the full safety and efficacy dataset: cohort sizes, nature and reversibility of Grade 3 events, discontinuations, dose-specific response, and whether investigators or regulators require changes. If toxicity forces a lower dose that weakens efficacy, the commercial and valuation impact could be substantial; if events are manageable and efficacy remains compelling, the initial selloff may prove excessive. Longer term, a credible safety profile is central to development and potential adoption, but this release alone does not establish either outcome. No peer or supplier exposure is sufficiently direct to justify a sector pair trade from these facts.

Key Decisions for Investors

• Do not treat the class-action announcement as a standalone short catalyst. It is an allegation/investigation notice, not evidence of liability; avoid adding exposure based solely on the legal headline.
• Keep TYRA on a clinical-event watchlist rather than initiate a directional position without updated price, valuation, and complete trial tables. Verify adverse-event types, cohort denominators, discontinuations, and dose-specific efficacy before sizing risk.
• Bear-case trigger: consider reducing or hedging TYRA if subsequent data show dose-limiting toxicity, weaker efficacy at a tolerable dose, a trial modification, or regulatory delay. These would indicate the safety issue affects development economics rather than merely sentiment.
• Bull-case falsifier of the negative thesis: detailed follow-up shows Grade 3 events are manageable and efficacy is retained at a tolerable dose, with no material protocol or regulatory setback. That would support reassessing whether the September repricing overreacted.
• Avoid options trades until current implied volatility, liquidity, and the next clinical catalyst date are verified; the lawsuit may inflate event premium without clarifying the underlying clinical risk.